Genflow Biosciences Plc is a biotechnology company based in the United Kingdom, specializing in the development of gene therapies aimed at addressing the biological mechanisms of aging. Founded in 2020 and with additional research facilities in Belgium, the company leverages advanced genetic engineering techniques to target the SIRT6 gene variant, a gene associated with longevity as observed in centenarians. Genflow’s primary focus is on innovating therapeutics that deliver this gene variant via adeno-associated virus (AAV) vectors, with the intention to extend healthspan and delay the onset of age-related diseases in humans and dogs. Its lead product, GF-1002, represents a gene therapy candidate designed for intravenous administration to potentially treat conditions such as metabolic dysfunction-associated steatohepatitis (MASH). The company also develops veterinary gene therapies, highlighting its cross-species research orientation. Through its research and development activities, Genflow Biosciences Plc contributes to the evolving landscape of longevity science and regenerative medicine, aiming to address the healthcare and societal challenges posed by an aging global population.